Eterna Therapeutics (Eterna Therapeutics) Short-Term Debt & Capital Lease Obligation : $2.22 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Eterna Therapeutics Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Eterna Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.22 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Eterna Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $39.63 Mil.

Eterna Therapeutics Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Eterna Therapeutics's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eterna Therapeutics Short-Term Debt & Capital Lease Obligation Chart

Eterna Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

0.80

0.43

0.30

2.22

Eterna Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial											0.30	0.17	0.17	1.15	2.22

Eterna Therapeutics Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Eterna Therapeutics Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Eterna Therapeutics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Eterna Therapeutics (Eterna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eterna Therapeutics Inc (NAS:ERNA) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141

Website

https://www.eternatx.com

Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Executives

Dorothy J Clarke	director	C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141
Charles Cherington	10 percent owner	ONE BOW STREET, CAMBRIDGE MA 02138
Brant Binder	director	C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066
Richard W Wagner	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451
Curtis W Huft	10 percent owner	4510 LAMESA HWY, SNYDER TX 79549
Freebird Partners Lp	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
Freebird Investments Llc	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
John D Halpern	10 percent owner
Nicholas Jason Singer	director	1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131
William A. Wexler	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Gregory Fiore	director	10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121
Andrew C. Jackson	officer: Chief Financial Officer	11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Matthew Angel	officer: Interim President and CEO	10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127
Heather B Redman	director	TWO NORTH NINTH STREET, ALLENTOWN PA 18101
Erin S. Enright	director	666 PLAINSBORO ROAD, PLAINSBORO NJ 08536